These breakthroughs underscore the therapeutic potential of precision modulation of the TR2/TR4 complex’s epigenetic activity, offering a causal intervention to ameliorate the pathological progression of hemoglobinopathies. The gene discussed is NR2C1; the disease is hemoglobinopathy.